Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down [Yahoo! Finance]
10x Genomics, Inc. (TXG)
Last 10x genomics, inc. earnings: 2/18 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
In the last reported quarter, the company's adjusted loss per share of 32 cents beat the Zacks Consensus Estimate by 31.9%. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Let's take a look at how things might have shaped up for GEHC prior to the announcement. 10x Genomics' top line is primarily driven by its two leading platforms — Visium and Zenium — in spatial biology and Chromium in single cell biology. The company's second-quarter results reflected strong contributions from Consumables while Instruments sales remained under pressure. The trend is likely to have continued in the soon-to-be-reported quarter. The spatial biology consumable sales are likely to have grown on the back of strong contributions from Visium HD (launched during the first quarter) as well as additional contributions from Xenium Prime 5K (launched during the second quarter). This growth is expected to have been further boosted by recovering Chromium consumables sales as cust
Show less
Read more
Impact Snapshot
Event Time:
TXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXG alerts
High impacting 10x Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
TXG
News
- Spatial Genomics and Transcriptomics Research Analysis Report 2024-2030: Emergence of High-Throughput Sequencing Platforms Fuels Market Growth [Yahoo! Finance]Yahoo! Finance
- Sphere Fluidics Strengthens Global Commercial Teams and Establishes Direct Sales and Support Channel in North America [Yahoo! Finance]Yahoo! Finance
- 10x Genomics to Present at the Wolfe Research 2024 Healthcare ConferencePR Newswire
- 10x Genomics, Inc. (NASDAQ: TXG) had its price target lowered by analysts at Barclays PLC from $21.00 to $19.00. They now have an "overweight" rating on the stock.MarketBeat
- Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts [Yahoo! Finance]Yahoo! Finance
TXG
Earnings
- 10/29/24 - Beat
TXG
Sec Filings
- 11/22/24 - Form 144
- 11/22/24 - Form 144
- 11/18/24 - Form 4
- TXG's page on the SEC website